Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Eli Lilly & Co. and Novo Nordisk A/S are competing for drug contracts in the aftermath of drug price scrutiny. Novo has managed to secure a contract with CVS, beating out its competitor. Other news is ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong ...

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...